Myriad Shares Fall Following Court Decision

Myriad's stock took a hit on Tuesday after a federal District Court declared the firm's BRCA gene patents were invalid.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.